EP4171232A4 - MODIFIED RELEASE FORMULATIONS OF MODIFIED FORMS OF TRIMETAZIDINE - Google Patents

MODIFIED RELEASE FORMULATIONS OF MODIFIED FORMS OF TRIMETAZIDINE Download PDF

Info

Publication number
EP4171232A4
EP4171232A4 EP21832842.5A EP21832842A EP4171232A4 EP 4171232 A4 EP4171232 A4 EP 4171232A4 EP 21832842 A EP21832842 A EP 21832842A EP 4171232 A4 EP4171232 A4 EP 4171232A4
Authority
EP
European Patent Office
Prior art keywords
modified
trimetazidine
release formulations
forms
modified release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21832842.5A
Other languages
German (de)
French (fr)
Other versions
EP4171232A1 (en
Inventor
Andrew D. LEVIN
Jaikrishna Patel
George MOONEY
Scott Herbig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imbria Pharmaceuticals Inc
Original Assignee
Imbria Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imbria Pharmaceuticals Inc filed Critical Imbria Pharmaceuticals Inc
Publication of EP4171232A1 publication Critical patent/EP4171232A1/en
Publication of EP4171232A4 publication Critical patent/EP4171232A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP21832842.5A 2020-06-30 2021-06-28 MODIFIED RELEASE FORMULATIONS OF MODIFIED FORMS OF TRIMETAZIDINE Pending EP4171232A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063046117P 2020-06-30 2020-06-30
US202063046115P 2020-06-30 2020-06-30
US202163183299P 2021-05-03 2021-05-03
US202163183294P 2021-05-03 2021-05-03
PCT/US2021/039303 WO2022005926A1 (en) 2020-06-30 2021-06-28 Modified release formulations of modified forms of trimetazidine

Publications (2)

Publication Number Publication Date
EP4171232A1 EP4171232A1 (en) 2023-05-03
EP4171232A4 true EP4171232A4 (en) 2024-07-24

Family

ID=79315460

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21832842.5A Pending EP4171232A4 (en) 2020-06-30 2021-06-28 MODIFIED RELEASE FORMULATIONS OF MODIFIED FORMS OF TRIMETAZIDINE

Country Status (8)

Country Link
EP (1) EP4171232A4 (en)
JP (1) JP2023531802A (en)
KR (1) KR20230028535A (en)
CN (1) CN116234555A (en)
AU (1) AU2021299197A1 (en)
CA (1) CA3187827A1 (en)
IL (1) IL299544A (en)
WO (1) WO2022005926A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250035269A (en) * 2023-09-05 2025-03-12 주식회사 뉴캔서큐어바이오 Coated tablet composition containing trimetazidine and method for preparing the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200138963A1 (en) * 2017-06-20 2020-05-07 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101466371B (en) * 2006-06-09 2011-10-05 施瓦茨制药有限公司 Stable pharmaceutical composition containing fesoterodine
PE20080669A1 (en) * 2006-09-08 2008-07-18 Drugtech Corp SUSTAINED RELEASE COMPOSITION INCLUDING LEVODOPA
ITFI20130184A1 (en) * 2013-08-01 2015-02-02 Valpharma Internat S P A PHARMACEUTICAL FORMULATION OF GLYCLAZIDE WITH MODIFIED RELEASE, ADMINISTRABLE BY ORAL ROUTE, AND ITS PRODUCTION METHOD.
NZ745921A (en) * 2016-03-09 2021-12-24 Nls 1 Pharma Ag A mazindol ir/sr multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (adhd)
US10980747B2 (en) * 2017-11-27 2021-04-20 Shin-Etsu Chemical Co., Ltd. Composition for solid preparation, solid preparation, and method for producing the same
CN109908096A (en) * 2017-12-12 2019-06-21 武汉武药科技有限公司 A kind of trimetazidine hydrochloride sustained-release tablets and preparation method thereof
EP3866794B1 (en) * 2018-10-17 2024-12-04 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200138963A1 (en) * 2017-06-20 2020-05-07 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism

Also Published As

Publication number Publication date
EP4171232A1 (en) 2023-05-03
IL299544A (en) 2023-02-01
JP2023531802A (en) 2023-07-25
CA3187827A1 (en) 2022-01-06
WO2022005926A1 (en) 2022-01-06
KR20230028535A (en) 2023-02-28
CN116234555A (en) 2023-06-06
AU2021299197A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
EP3924352A4 (en) CRYSTALLINE FORMS OF AN RSK INHIBITOR
EP3870178A4 (en) CRYSTALLINE FORMS OF MNK INHIBITORS
EP3843704A4 (en) MULTIKINASE INHIBITOR EMULSION FORMULATIONS
MA54526A (en) NEW POLYMORPHIC FORMS OF A TGFBeta INHIBITOR
EP3871361A4 (en) RELEASE TO AN SA SAFETY ASSOCIATION
EP3866801A4 (en) DEGRADING AGENTS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 KINASE
EP3402521A4 (en) INHIBITION OF ALLERGIC REACTION USING IL-33 INHIBITOR
EP3456722A4 (en) CRYSTALLINE FORMS OF FREE CRISABOROLE AND PREPARATION METHOD AND USE THEREOF
EP3955910A4 (en) EXTENDED RELEASE FORMULATIONS
EP3500349A4 (en) EXTENDED RELEASE BIO-REMEDIAL COMPOSITION FOR REMOVAL OF ENERGY COMPOUNDS FROM CONTAMINATED ENVIRONMENTS
EP3870181A4 (en) CRYSTALLINE FORMS OF AN ALK2 INHIBITOR
IL313254A (en) Vaccine formulations against corona
EP3810118A4 (en) FORMULATIONS OF TEGAVIVINT AND RELATED COMPOUNDS
EP3722372A4 (en) COMPOSITION OF CURING SILICONE-BASED RELEASE AGENT
EP4171232A4 (en) MODIFIED RELEASE FORMULATIONS OF MODIFIED FORMS OF TRIMETAZIDINE
EP3836938A4 (en) SOLID FORMS OF SUBSTITUTED BENZOXABOROLE AND RELATED COMPOSITIONS
EP3512518A4 (en) BACKGROUND OF THE INVENTION OF EXTENDED RELEASE BUPRENORPHINE FORMULATIONS
EP3946296A4 (en) PHARMACEUTICAL EXTENDED RELEASE FORMULATION
MA49704A (en) ISOTOPIC-LABELED BILIARY ACID DERIVATIVES
EP4506208A4 (en) RELEASE ARRANGEMENT
EP4369934A4 (en) CRYSTALLINE FORMS OF TROFINETIDE
DK3886813T3 (en) Pharmaceutical formulations of cyclosporine analogs
ES1229119Y (en) QUICK RELEASE MECHANISM FOR REMOVABLE CONNECTION OF TWO OBJECTS
EP3740204A4 (en) SOLID STATE FORMS OF FASORACETAM
EP4284362A4 (en) FORMULATIONS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230511

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A01N0043040000

Ipc: A61K0009200000

A4 Supplementary search report drawn up and despatched

Effective date: 20240620

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/00 20060101ALI20240614BHEP

Ipc: A61K 31/496 20060101ALI20240614BHEP

Ipc: A61K 9/20 20060101AFI20240614BHEP